- Canalevia ™ -CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for DAD in dogs to receive any type of FDA approval.
- US veterinarians, veterinary oncologists, and members of the media can click here to register for the CID Treatment Forum; Remote access will be available for participants unable to attend in person
SAN FRANCISCO, CA / ACCESSWIRE / January 12, 2022 / Jaguar Health, Inc. (NASDAQ: JAGX), under its trade name Jaguar Animal Health for the veterinary market, today announced that the company is hosting a Veterinarian Treatment Forum on Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday the 16th January from 6 p.m. to 8 p.m. Eastern at the Veterinary Meeting & Expo (VMX) conference in Orlando, Florida.
Renowned veterinary oncologist, Dr. Craig A. Clifford, DVM, MS, DACVIM will lead the discussion on the significant disease burden of chemotherapy-induced diarrhea disease, share his experience in treating dogs with DIC and characterize the profile clinic of Canalevia-CA1, the company’s herbal prescription drug for the treatment of DIC in dogs. Remote access to the event will be available to registered veterinarians and members of the media who cannot attend the ICD Treatment Forum in person. Dinner will be offered to participants in person.
Details of participation in the CID Treatment Forum:
- Date and time of the event: Sunday, January 16, 2022, 6 p.m. to 8 p.m. Eastern Time
- Location of the event: Lounge 16 at the Rosen Center Hotel, which is adjacent to the Orange County Convention Center (the location of VMX)
- How to register: US veterinarians, veterinary oncologists and members of the media can register on the Canalevia.com site for the CID Treatment Forum by clicking on here
- Remote access: Live remote access to the event will be available to registered U.S. veterinarians and members of the media who cannot attend the CID Treatment Forum in person.
As part of the launch of Canalevia-CA1, the company is showcasing the product on its exhibit booth at VMX, which will take place January 15-19, 2022 at the Orange County Convention Center in Orlando, Florida. Canalevia-CA1 is marketed as a prescription drug under the company’s brand name Jaguar Animal Health. Jaguar Animal Health will be present at VMX booth number 4610.
Additional information on VMX, the largest annual educational event for the US veterinary industry, is available on the conference website by clicking here.
About chemotherapy-induced diarrhea (CID) in dogs
Due to the increasing number of chemotherapeutic agents adopted by veterinarians and veterinary oncologists, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have shown that the incidence of CID is one of the three most common side effects in dogs on cancer treatment1, and managing side effects such as diarrhea can be important in maintaining effective cancer treatment. More than half of U.S. veterinarians who responded to a recent Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID. .
Crofelemer is a new oral herbal medicine extracted and purified from the red bark sap, also called ‘dragon’s blood’, medicine Lechleri croton tree in the Amazon rainforest. Jaguar Health’s wholly owned subsidiary Napo Pharmaceuticals has implemented a sustainable harvest program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity and support to indigenous communities. Additionally, crofelemer is the active ingredient in an antidiarrhoeal drug approved by the FDA under botanical guidelines and indicated for the symptomatic relief of non-infectious diarrhea in adult human patients with HIV / AIDS receiving antiretroviral therapy.
Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral herbal prescription product that is conditionally approved by the FDA to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a specific canine formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from Lechleri croton tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows the product to come to market while Jaguar continues to gather the substantial evidence of efficacy required for full approval. Jaguar has received minor use in a major species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. The FDA has established a threshold of “small numbers” for minor use in each of the seven main species covered by the MUMS Act. The low count threshold is currently 70,000 for dogs, which is the largest number of dogs that can be affected by any disease or condition in a year and whose use is still considered minor use. .
Important safety information on Canalevia-CA1
For oral use in dogs only. Do not use in humans. Keep Canalevia™-CA1 (crofelemer delayed-release tablets) in a safe place out of the reach of children and other animals. Consult a physician in the event of accidental ingestion by humans. Do not use in dogs with known hypersensitivity to crofelemer. Before using Canalevia-CA1, rule out the infectious etiologies of the diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common side effects included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts the use of this drug by or on the order of a licensed veterinarian. Use only as directed. It is a violation of federal law to use this product other than as directed on the labeling. Conditionally approved by the FDA pending full demonstration of efficacy under application number 141-552.
About Jaguar Health, Inc., Jaguar Animal Health, Napo Pharmaceuticals, Inc. and Napo Therapeutics SpA
Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on the development of novel, herbal, non-opioid, and derivative prescription drugs in a sustainable manner for people and animals with gastrointestinal disorders, particularly chronic and debilitating diarrhea. Jaguar Animal Health is a trade name of Jaguar Health. Jaguar Health’s wholly owned subsidiary, Napo Pharmaceuticals, Inc., is focused on the development and commercialization of proprietary human gastrointestinal pharmaceuticals herbal from plants responsibly harvested from rainforest areas. Napo Therapeutics SpA, the Italian subsidiary majority-owned by Napo Pharmaceuticals, is focused on expanding access to crofelemer in Europe.
For more information on Jaguar, please visit https://jaguar.health. For more information on Napo Pharmaceuticals, visit www.napopharma.com. For more information on Napo Therapeutics, visit www.napotherapeutics.com.
Certain statements contained in this press release constitute “forward-looking statements”. These include statements regarding Jaguar’s expectations for attending the VMX 2022 conference and the expectation that the company holds a CID processing forum on January 16, 2022 during VMX. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expect”, “plan”, “aim”, “anticipate”, “could”, “Intend,” “target”, “project”, “contemplate”, “believe”, “estimate”, “predict”, “potential” or “continue” or the negative of these or other similar terms . The forward-looking statements contained in this press release are only predictions. Jaguar has based these forward-looking statements in large part on its current expectations and projections regarding future events. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Some of the factors that could affect our actual results are included in the periodic form reports. 10-K and for mular 10-Q that we file with the Securities and Exchange Commission. Unless required by applicable law, Jaguar does not intend to publicly update or revise any forward-looking statements contained in this document, whether as a result of new information, future events, or changes in circumstances. or otherwise.
1Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomized controlled study. J Small Anim Pract. 2014; 55: 391-398
Jaguar Health, Inc.
THE SOURCE: Jaguar Health, Inc.
See the source version on accesswire.com: